At RD Day in June 2023  Taysha provided an overview of new comprehensive data analysis and development of diseaseprogression model DPM which the Company believes has the potential to address FDA feedback regarding the heterogeneity of GAN and effortdependent nature of MFM32 as the primary endpoint in an unblinded study New comprehensive data analysis utilizing the DPM submitted as meeting request to the FDA feedback for a potential regulatory pathway for TSHA120 expected in Q3 2023 FDA feedback on CMC module 3 amendment concluded that the analytical data is sufficient to support the comparability of pivotal lot and release for use in clinical studies Second Quarter 2023 Financial Highlights Research and Development Expenses Research and development expenses were 198 million for the three months ended June 30 2023  compared to 235 million for the three months ending June 30 2022 